Active, not recruitingPHASE2, PHASE3NCT06031259

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Studying Mucopolysaccharidosis type 2

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Idursulfase-IT(drug)
Enrollment: 6 enrolled
Eligibility: 3-19 years · MALE
Timeline: 2024 – 2029

Study locations (4)

M.A.G.I.C. Clinic, Calgary, Alberta, Canada
University of British Columbia, Vancouver, British Columbia, Canada
Hospital for Sick Children, Toronto, Ontario, Canada
Hopital Femme Mere Enfant, Bron, Auvergne-Rhône-Alpes, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06031259 on ClinicalTrials.gov

← Back to all trials